twitter   linkedin

KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.

The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.

We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

  • Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
  • Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
  • Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.

The KMT MouseTM is your essential tool for therapeutics and vaccine development.

News and Events

  1. Killam image small

    Hepatitis B and C - Rapidly Evolving Treatments

    January 20 2016

    TED-Talk with 2015 Canada Council Killam Laureate Dr. L. Tyrrell

  2. Hepatitis virus

    The ABCs of Hepatitis

    November 20 2015

    An overview of all Hepatitis viruses (with HDV and HEV), including the note "mice with grafted human liver cells are proving to be valuable models"

  3. BIO-Europe image

    BIO-Europe 2015

    October 20 2015

    KMT Hepatech representative to attend major European Partnering conference

  4. »more